State-of-the-art and emerging antivirals for chronic hepatitis B infection

References

• WHO Hepatitis B Report, 27 July 2021, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
   Google Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2017 July;92(27):369–392.
   PubMedGoogle Scholar
• https://cdafound.org/premium-dashboard/ Cited 2022 Jan 26.
   Google Scholar
• https://www.who.int/news-room/fact-sheets/detail/hepatitis-b Cited 2022 Jan 26.
   Google Scholar
• Thomas DL, Longo DL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380(21):2041–2050.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Horn J, Krause G, et al., Time trends of chronic HBV infection over prior decades – a global analysis. J Hepatol. 2017;66(1): 48–54.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Brosgart CL, Welch S, et al. An updated assessment of chronic hepatitis B prevalence among foreign‐born persons living in the United States. Hepatology. 2021;74(2):607–626.
   PubMed Web of Science ®Google Scholar
• Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver‐related outcomes and all‐cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539–548.
   PubMed Web of Science ®Google Scholar
• Wong GL, Wong VW, Yuen BW, et al. An aging population of chronic hepatitis B with increasing comorbidities: a territory‐wide study from 2000 to 2017. Hepatology. 2020;71(2):444–455.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Sypsa V, Dalekos G, et al., Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018;68(6): 1129–1136.
   PubMed Web of Science ®Google Scholar
• G V P, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8(3):167–178.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63(5):1481–1492.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al., Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2): 348–356.
   PubMed Web of Science ®Google Scholar
• Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B. Best Pract Res Clin Gastroenterol. 2017;31(3):257–264.
   PubMed Web of Science ®Google Scholar
• McNaughton AL, D’Arienzo V, Ansari MA, et al., Insights from deep sequencing of the HBV genome—unique, tiny, and misunderstood. Gastroenterology. 2019;156(2): 384–399.
   PubMed Web of Science ®Google Scholar
• Li W, Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes: basic insights and clinical implications. J Hepatol. 2016;64(1):S32–S40.
   PubMedGoogle Scholar
• Martinez MG, Boyd A, Combe E, et al. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75(3):706–717.
   PubMed Web of Science ®Google Scholar
• Tu T, Zehnder B, Qu B, et al. De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. JHEP Rep. 2021;3(1):100195.
   PubMedGoogle Scholar
• Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22(1):19–32.
   PubMed Web of Science ®Google Scholar
• Bousali M, Papatheodoridis G, Paraskevis D, et al. Hepatitis B virus DNA integration, chronic infections and hepatocellular carcinoma. Microorganisms. 2021;9(8):1787.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Locarnini S, Pollicino T, et al., Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2): 397–408.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok AS, McMahon BJ, et al., Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4): 1560‐99.
   Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al., EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2): 370–398.
   PubMed Web of Science ®Google Scholar
• Liu C-J, Kao J-H. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013;33(2):97–102.
   PubMed Web of Science ®Google Scholar
• Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014;20(18):5427.
   PubMed Web of Science ®Google Scholar
• Cornberg M, Lok AS, Terrault NA, et al., Guidance for design and endpoints of clinical trials in chronic hepatitis B—report from the 2019 EASL‐AASLD HBV treatment endpoints conference. J Hepatol. 2020;72(3): 539–557.
   PubMed Web of Science ®Google Scholar
• Jeng WJ, Papatheodoridis G, Lok ASF. Hepatitis B virus infection. Lancet. in press. 2022.
   Google Scholar
• Papatheodoridis GV, Chan HLY, Hansen BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62(4):956–967.
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26(8):936–941.
   PubMed Web of Science ®Google Scholar
• Yip TC, Wong GL, Chan HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70(3):361–370.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection – EASL special conference. J Hepatol. 2015;63(5):1238–1253.
   PubMed Web of Science ®Google Scholar
• Kang C, Syed YY. Bulevirtide: first Approval. Drugs. 2020;80(15):1601–1605.
   PubMed Web of Science ®Google Scholar
• Zhao K, Liu S, Chen Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the post entry  step is inhibited by the entry inhibitor Myrcludex B. Emerg Microb Infect. 2018;7. 186.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Aleman S, Brunetto M, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. J Hepatol. 2022;77:S4–S5.
   Web of Science ®Google Scholar
• Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without PegIFNα for patients with compensated chronic hepatitis delta: from clinical trials to real life studies. J Hepatol. 2022;S0168-8278(22):7.
   Google Scholar
• Khan IW, Dad Ullah MU, Choudhry M, et al. Novel therapies of hepatitis B and D. Microorganisms. 2021;9(12):2607.
   PubMed Web of Science ®Google Scholar
• Guo F, Zhao Q, Sheraz M, et al. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog. 2017;13(9):e1006658.
   PubMed Web of Science ®Google Scholar
• Taverniti V, Ligat G, Debing Y, et al. Capsid assembly modulators as antiviral agents against HBV: molecular mechanisms and clinical perspectives. J Clin Med. 2022;11(5):1349.
   PubMed Web of Science ®Google Scholar
• Yan Z, Wu D, Hu H, et al. Direct inhibition of hepatitis B e antigen by core protein allosteric modulator. Hepatology. 2019;70(1):11–24.
   PubMed Web of Science ®Google Scholar
• Bartoli A, Gabrielli F, Tassi A, et al. Treatments for HBV: a glimpse into the future. Viruses. 2021;13(9):1767.
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Zhou X, Gane E, et al., Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol. 2021;6(9): 723–732.
   PubMed Web of Science ®Google Scholar
• Hou J, Gane E, Zhang W, et al. Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients. J Hepatol. 2022;77:S299.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Balabanska R, Hou J, et al. Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naïve chronic hepatitis B patients: 48-week treatment and posttreatment follow-up. J Hepatol. 2022;77:S867.
   Web of Science ®Google Scholar
• Yuen M-F, Agarwal K, Gane EJ, et al., Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5(2): 152–166.
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Agarwal K, Ma X, et al. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J Hepatol. 2022;S0168-8278(22):8.
   Google Scholar
• Berke JM, Dehertogh P, Vergauwen K, et al. Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379. Antimicrob Agents Chemother. 2020;64(5):e02439–19.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Lenz O, Vandenbossche JJ, et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology. 2020;159(2):521–533.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang F, Zhu X, et al. Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection. Clin Infect Dis. 2021;73(2):175–182.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Schwabe C, Berliba E, et al. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother. 2022;77(4):1102–1110.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Yuen M, Jucov A, et al. Safety, pharmacokinetics (PK), and antiviral activity of the capsid assembly modulator (CAM) ALG-000184 in subjects with chronic hepatitis B (CHB). Hepatology. 2021;74:516A–517A.
   Web of Science ®Google Scholar
• Yuen M-F, Agarwal K, Gane E, et al. Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B. J Hepatol. 2022;77:S835–S836.
   Web of Science ®Google Scholar
• Feld J, Lawitz E, Nguyen TT, et al. EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in Nuc suppressed chronic hepatitis B patients. J Hepatol. 2022;77:S848.
   Web of Science ®Google Scholar
• Yuen M-F, Chuang W-L, Peng C-Y, et al. EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients. J Hepatol. 2022;77:S849.
   PubMed Web of Science ®Google Scholar
• Hui RW-H, Mak L-Y, Seto W-K, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Molec Hepatol. 2022;28(3):408–424.
   PubMed Web of Science ®Google Scholar
• Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol. 2005;79(2):1027–1035.
   PubMed Web of Science ®Google Scholar
• Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133–147.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Viral vectors applied for RNAi-based antiviral therapy. Viruses. 2020;12(9):924.
   PubMed Web of Science ®Google Scholar
• H-l W, Huang L-R, Huang -C-C, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology. 2005;128(3):708–716.
   PubMed Web of Science ®Google Scholar
• Shih Y-M, Sun C-P, Chou -H-H, et al. Combinatorial RNA interference therapy prevents selection of pre-existing HBV variants in human liver chimeric mice. Sci Rep. 2015;5(1):15259.
   PubMedGoogle Scholar
• Yuen MF, Berliba E, Kim YJ, et al. Pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection. Hepatology. 2020;72:62A–63A.
   Google Scholar
• Yuen M-F, Berliba E, Sukeepaisarnjaroen W, et al. Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. J Hepatol. 2022;77:S876–S877.
   Web of Science ®Google Scholar
• Thi EP, Yuen MF, Gane E, et al. Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA. J Hepatol. 2021;75:S760.
   Web of Science ®Google Scholar
• Paratala BS, Park JJ, Ganchua SC, et al. Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers. J Hepatol. 2021;75:S761.
   Web of Science ®Google Scholar
• Gane E, Lim Y-S, Cloutier D, et al. Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results. J Hepatol. 2022;75:S287–S288.
   Web of Science ®Google Scholar
• Yuen M-F, Lim Y-S, Cloutier D, et al. Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection. Hepatology. 2021;74:63A.
   Web of Science ®Google Scholar
• Lim Y-S, Yuen M-F, Cloutier D, et al. Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection. J Hepatol. 2022;77:S69–S70.
   Web of Science ®Google Scholar
• Yuen M-F, Lim T-H, Kim W, et al. HBV RNAi inhibitor RG6346 in phase 1b-2a trial was safe, well tolerated, and resulted in substantial and durable reductions in serum HBsAg levels. AASLD The Liver Meeting 2020 Nov 11-16 USA LB-P12
   Google Scholar
• Gane E, Locarnini S, Lim TH, et al. Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors. J Hepatol. 2021;75:S289–S290.
   Web of Science ®Google Scholar
• Gane E, Yuen M, Kim DJ, et al. Clinical study of single‐stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology. 2021;74(4):1795–1808.
   PubMed Web of Science ®Google Scholar
• Yuen M-F, Heo J, Jang J-W, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med. 2021;27(10):1725–1734.
   PubMed Web of Science ®Google Scholar
• Lim S-G, Pojoga C, Janssen H, et al. Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study. J Hepatol. 2022;77:S12–S13.
   PubMedGoogle Scholar
• Yuen M-F, Plesniak R, Lim S-G, et al. Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study. J Hepatol. 2022;77:S13.
   Google Scholar
• Michler T, Kosinska AD, Festag J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 2020;158(6):1762–1775.
   PubMed Web of Science ®Google Scholar
• Noordeen F, Scougall CA, Grosse A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLOS One. 2015;10(11):e0140909.
   PubMed Web of Science ®Google Scholar
• Al-Mahtab M, Bazinet M, Vaillant A. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLOS One. 2016;11(6):e0156667.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pântea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2017;2(12):877–889.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pântea V, Cebotarescu V, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta virus coinfection. Hepatol Communic. 2021;5(2):189–202.
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pântea V, Placinta G, et al., Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology. 2020;158(8): 2180–2194.
   PubMed Web of Science ®Google Scholar
• Hershkovich L, Bazinet M, Pantea V. HBsAg, anti-HBs and ALT kinetic characterization during NAP based combination therapy of HBeAg negative chronic hepatitis B infection. J Hepatol. 2021;75:S50.
   Google Scholar
• Replicor, press release, 2021 Nov 1. http://replicor.com/replicor-announces-transition-of-rep-2139-mg-to-subcutaneous-administration-at-aasld-2021/
   Google Scholar
• Sekiba K, Otsuka M, Ohno M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx–DDB1 interaction. Cell Mol Gastroenterol Hepatol. 2019;7(2):297–312.
   PubMed Web of Science ®Google Scholar
• Rossignol J, Bréchot C. A Pilot Clinical Trial of Nitazoxanide in the treatment of chronic hepatitis B. Hepatol Communic. 2019;3(6):744–747.
   PubMed Web of Science ®Google Scholar
• Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479–480:131–145.
   PubMed Web of Science ®Google Scholar
• Bockmann J-H, Stadler D, Xia Y, et al. Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus–infected hepatocytes. J Infect Dis. 2019;220(4):567–577.
   PubMed Web of Science ®Google Scholar
• Xia Y, Stadler D, Lucifora J, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150(1):194–205.
   PubMed Web of Science ®Google Scholar
• Ramanan V, Shlomai A, Cox DBT, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5(1):10833.
   PubMedGoogle Scholar
• Kostyushev D, Brezgin S, Kostyusheva A, et al. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci. 2019;76(9):1779–1794.
   PubMed Web of Science ®Google Scholar
• Ates I, Rathbone T, Stuart C, et al. Delivery approaches for therapeutic genome editing and challenges. Genes (Basel). 2020;11(10):1113.
   PubMed Web of Science ®Google Scholar
• Mouzannar K, Fusil F, Lacombe B, et al. Farnesoid X receptor-α is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J. 2019;33(2):2472–2483.
   PubMed Web of Science ®Google Scholar
• Scalfaro P, Heo J, Liu C-J, et al. A phase 2 study testing FXR agonist vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results. J Hepatol. 2021;75:S761.
   Google Scholar
• Yuen M-F, Asselah T, Jacobson I, et al. Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): results from the REEF-1 study. J Hepatol. 2022;77:S864–S865.
   Web of Science ®Google Scholar
• Agarwal K, Buti M, van Bommel F, et al. Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study. J Hepatol. 2022;77:S8.
   Web of Science ®Google Scholar
• Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: implications for finite treatment strategies in HBV ‘cure.’ J Hepatol. 2022;77(1):245–248.
   PubMed Web of Science ®Google Scholar